[1] Allouch S, Malki A, Allouch A et al. High-risk HPV oncoproteins and PD-1/PD-L1 interplay in human cervical cancer: recent evidence and future directions[J]. Frontiers in Oncology, 10, 914(2020).

[2] HUANG He, LIU Jihong. Standardization of postoperative adjuvant treatment for cervical cancer[J]. Chinese Journal of Practical Gynecology and Obstetrics, 37, 51-54(2021).

[3] Small W, Mell L K, Anderson P et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer[J]. International Journal of Radiation Oncology, 71, 428-434(2008).

[4] LIN Saixia. Application of contrast agent in computed tomography of cervical cancer[J]. Strait Pharmaceutical Journal, 19, 85-86(2007).

[5] Quan E M, Li X Q, Li Y P et al. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment[J]. International Journal of Radiation Oncology, 83, 1169-1178(2012).

[6] LIN Lihong, GUO Yu. Preliminary study on clinical application of silver clip labeling method in target area delineation of intensity modulated radiotherapy[J]. Journal of Medical Information, 27, 560-561(2014).

[7] HU Lijuan, ZHANG Jing, ZHOU Min et al. Dosimetric study of volumetric intensity-modulated arc therapy and intensity modulated radiation therapy in postoperative radiotherapy for cervical cancer with ovarian preservation[J]. The Practical Journal of Cancer, 37, 1851-1854(2022).

[8] GAO Junfeng. Dosimetric comparison of conformal, intensity-modulated and conventional pelvic radiotherapy plans in posthysterectomy cervical cancer patients[D], 11-15(2011).

[9] Kim H J, Chang A R, Park Y K et al. Dosimetric effect of CT contrast agent in CyberKnife treatment plans[J]. Radiation Oncology, 8, 244(2013).

[10] Denham J W, Hauer-Jensen M. The radiotherapeutic injury: a complex 'wound'[J]. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 63, 129-145(2002).

[11] GU Wendong, LI Qilin, GAO Min et al. Impact of oral contrast agent for assisting in outlining small bowel on pelvic VMAT dose in patients with cervical cancer[J]. Chinese Journal of Radiation Oncology, 23, 472-474(2014).

[12] Ramm U, Damrau M, Mose S et al. Influence of CT contrast agents on dose calculations in a 3D treatment planning system[J]. Physics in Medicine and Biology, 46, 2631-2635(2001).

[13] YANG Ruijie, WANG Wenbao, ZHANG Yue et al. Effect of intravenous contrast agent on dose distribution in treatment planning for postoperative whole pelvic radiotherapy of gynecologic cancer[J]. Journal of Practical Oncology, 25, 311-314(2010).